Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Agilent Obtains IVD Patent Licenses From Abbott

By HospiMedica staff writers
Posted on 08 Sep 2006
Agilent Technologies Inc. More...
(Palo Alto, CA, USA), has obtained worldwide, non-exclusive patent licenses from Abbott Molecular Inc.(Des Plaines, IL, USA), that cover microarray applications, including in vitro diagnostics (IVD), commercial laboratories, and research.

More specifically, the applications will be for the manufacture, marketing, and sale of oligonucleotide microarrays using a two-or-more color technology for gene expression and comparative genomic hybridization (CGH) applications. Expressly built into the grant of rights are related products, instruments, components and services. Other details of the licensing agreement were not disclosed.

"This intellectual property complements other recent Agilent investments in microarray fabrication technology and software,” said Nick Roelofs, vice president and general manager of Agilent's Life Sciences Solutions Unit.

Oligonucleotide microarrays comprise short sequences of nucleotides, often used as probes for detecting complementary DNA or RNA. Array CGH technology provides a way of studying chromosomal aberrations, including copy number changes and rearrangements, across the entire genome simultaneously. Ultimately, this information can be used to determine gene activity or to pinpoint chromosomal abnormalities such as gains or losses associated with disease states.

Agilent Technologies is a leading worldwide provider of microarray-based genomics research solutions. The company's product portfolio includes reagents for sample preparation and microarray processing, systems for sample quality control (QC) and high-throughput microarray scanning, 60-mer oligo microarrays and custom microarray design services, and industry-leading informatics tools, including GeneSpring and Rosetta Resolver.

Abbott Molecular provides doctors with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for an early diagnosis, selection of therapy, and monitoring of disease progression.



Related Links:
Agilent Technologies
Abbott Molecular

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.